Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “buy” rating reiterated by research analysts at Stifel Nicolaus in a note issued to investors on Wednesday.

Several other research firms have also commented on BDX. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 17th. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $194.69.

Shares of Becton, Dickinson and (BDX) opened at 196.63 on Wednesday. The firm’s 50-day moving average is $198.24 and its 200 day moving average is $186.80. The stock has a market capitalization of $41.94 billion, a P/E ratio of 32.66 and a beta of 1.05. Becton, Dickinson and has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.35 earnings per share. On average, equities research analysts forecast that Becton, Dickinson and will post $9.46 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Receives “Buy” Rating from Stifel Nicolaus” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/becton-dickinson-and-company-bdx-receives-buy-rating-from-stifel-nicolaus.html.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in BDX. BlackRock Inc. increased its position in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Becton, Dickinson and by 185.3% in the second quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock worth $177,401,000 after buying an additional 590,494 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Becton, Dickinson and during the first quarter worth approximately $101,993,000. Finally, Waverton Investment Management Ltd bought a new position in shares of Becton, Dickinson and during the second quarter worth approximately $68,448,000. Hedge funds and other institutional investors own 75.71% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.